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Abstract: Preserving skeletal muscle mass and functional capacity is essential for healthy ageing.
Transient periods of disuse and/or inactivity in combination with sub-optimal dietary intake have
been shown to accelerate the age-related loss of muscle mass and strength, predisposing to disability
and metabolic disease. Mechanisms underlying disuse and/or inactivity-related muscle deterioration
in the older adults, whilst multifaceted, ultimately manifest in an imbalance between rates of muscle
protein synthesis and breakdown, resulting in net muscle loss. To date, the most potent intervention
to mitigate disuse-induced muscle deterioration is mechanical loading in the form of resistance
exercise. However, the feasibility of older individuals performing resistance exercise during disuse
and inactivity has been questioned, particularly as illness and injury may affect adherence and safety,
as well as accessibility to appropriate equipment and physical therapists. Therefore, optimising
nutritional intake during disuse events, through the introduction of protein-rich whole-foods, isolated
proteins and nutrient compounds with purported pro-anabolic and anti-catabolic properties could
offset impairments in muscle protein turnover and, ultimately, the degree of muscle atrophy and
recovery upon re-ambulation. The current review therefore aims to provide an overview of nutritional
countermeasures to disuse atrophy and anabolic resistance in older individuals.
Keywords: skeletal muscle; atrophy; nutrition; disuse; ageing; inactivity; metabolism; protein
1. Introduction
Human skeletal muscle mass and strength are of great importance for maintaining cardio-metabolic
health and locomotion in older age [1]. With advancing age, a loss of muscle mass and strength is
observed (sarcopenia), increasing the risk of falls, fractures and mortality [2]. The age-related decline
in muscle mass and strength occurs at an annual rate of ~1% and 3%, respectively, from the fifth
decade of life onwards [3,4]. Sarcopenia is estimated to affect as many as ~32 million older individuals
across Europe in the coming decades [5], at an annual cost to the UK health services of ~£2.5 billion
(1.2% of GDP). Therefore, developing strategies to counteract this phenomenon are essential to extend
the number of years lived in good health, as well as reduce the burden on health care systems and the
global economy.
The maintenance of human skeletal muscle hinges on the dynamic balance between muscle
protein synthesis (MPS) and muscle protein breakdown (MPB). To increase skeletal muscle mass, MPS
must exceed MPB, which can be achieved by performing regular resistance exercise training (RET) in
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combination with adequate protein nutrition [6,7]. However, whilst young individuals demonstrate
a pronounced response to these anabolic stimuli, a blunted response has been observed in older
adults [8]. Indeed, maximal stimulation of MPS occurs at much lower relative dosages in younger
adults (~0.24 g·kg−1·BW), compared with older adults (~0.4 g·kg−1·BW) [9]. The phenomenon of
“anabolic resistance” in older adults was first established by Volpi and colleagues, who infused older
adults intravenously with an amino acid-glucose mixture thereby bypassing splanchnic uptake [10].
Following a ~3-h infusion period, a blunted MPS response was observed in older compared with
younger adults [10]. This was subsequently confirmed in seminal work by Cuthbertson et al. [11]
following an oral dose–response (i.e., 0, 2.5, 5, 10, 20 and 40 g) of crystalline essential amino acids
(EAAs). The authors observed a maximally stimulating effect of ~10 g of EAAs in younger adults;
however, a large (~40 g) bolus failed to elicit similar increases in MPS to the smaller ~10 g provision
observed in younger adults and is likely explained by a decrease in postprandial anabolic sensitivity
and diminished mTORC1 phosphorylation in older adults [11]. This age-related anabolic resistance is
likely an important driving factor in age-related muscle loss and, importantly, is exacerbated during
intermittent periods of musculoskeletal disuse and reduced physical activity (PA) [12,13]. Furthermore,
anabolic resistance can also occur in younger adults following brief periods of disuse [14,15], although
evidence suggests that younger individuals recover losses in muscle mass and strength at a quicker rate
than older individuals upon re-ambulation (Figure 1) [16,17]. These transient and intermittent episodes
of inactivity result in significant muscle wasting, predominantly in the lower limbs, affecting activities
of locomotion and daily living. Indeed, it has been shown that five days of bed-rest (BR) results in
quadriceps muscle loss equivalent to ~5 years of ageing [18]. This disuse-induced accelerated model of
sarcopenia leads to a downward spiral of health, resulting in a greater risk of hospital (re)admission
and an increased length of hospital stay [19,20]. In 2017, ~18.7 million adult hospital admissions were
recorded, of which ~7.6 million were aged 65 and over [21]. Simultaneously bed occupancy rates
soared to nearly 90% in the UK [22]. As a result, minimising muscle deterioration during disuse events
in older individuals will likely reduce the length of hospital stay, complications following discharge
and readmission rates to inpatient facilities.
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Attenuation of Muscle Loss
Enhanced Recovery of Muscle
Some Older Adults May 
Never Fully Recover
Figure 1. Skeletal muscle atrophy younger and older adults in response to a period of unloading and a
subsequent period of exercise rehabilitation. The black dotted lines indicate phenotypical differences in
absolute levels of muscle mass. The yellow dotted line indicates a level in which low levels of leg lean
mass results in disability and reduced functional ability (i.e., disability threshold). The red line indicates
traditional trajectory in loss of muscle mass observed by disuse. The green dotted line indicates the
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potential of a nutritional strategy to offset muscle loss during disuse and improve rates of recovery
following reambulation and rehabilitation. Importantly, the red dotted line indicates a proportion
of older adults may not return to pre-disuse levels of muscle mass, particularly in the absence of
aggressive retraining (Adapted from Perkin et al. 2016 [17]).
2. Experimental Models of Disuse and Inactivity
Several experimental models have been used to explore the effects of reduced PA and/or disuse on
human skeletal muscle mass. The use of step-reduction (SR) in experimental research is highly relevant
to numerous situations of old age in which activity levels are reduced, including transient periods of
inactivity (e.g., illness and elective surgery) [23]. Previous investigations using SR typically reduce daily
step-count to ≤2000/day over 7–14 days [12,15,24]. To place this in context, ~750 steps/day represents
typical ambulatory activity during an acute hospital stay [12,15,23]. SR studies consistently show a
reduction in postprandial [12] and free-living MPS [15,24], as well as marked reductions in muscle
mass [12]. Another model of disuse atrophy, with clinical relevance, is unilateral limb immobilisation
(ULI), achieved by the casting (or bracing) of a given limb over days to weeks [14,25], with the
non-immobilised contralateral limb often serving as a within-subject control [26]. During ULI, limbs
can be immobilised at specific angles to investigate the effects of passive shortening or lengthening
on muscle fibres, thereby inducing significant muscle atrophy and strength loss. Mechanistically,
ULI has consistently been reported to impair postabsorptive [27], postprandial [14,28] and free-living
MPS [29] and elevate markers of proteolysis [30,31]. The use of bed-rest (BR) in experimental research
has also provided an excellent platform to enhance understanding of the impacts of reduce PA on
skeletal muscle health, particularly in older individuals [32–34]. This mode of disuse is of particular
importance as older individuals experience a greater number of hospital admissions that typically
last for 5–6 days on average and are particularly vulnerable to metabolic complications. Experimental
studies of BR typically occur over 5–14 days [32,33,35], but ~28 days [36,37] and ~90 days of BR with
a 6◦ head-down tilt (to mimic spaceflight) [38] have also been used. Similar to other disuse models,
BR has been reported to impair postabsorptive [39], postprandial [40] and free-living MPS [41] and
elevate markers of proteolysis [18], as well as reduce muscle mass, strength and function [42].
Undoubtedly, studies implementing these experimental models of disuse and inactivity have
furthered our understanding of the mechanisms regulating muscle deconditioning during unloading.
However, questions remain around the clinical relevance and translation of these studies to patient
populations. Specifically, whilst younger and older research volunteers are likely to be in good health,
older patients admitted to hospital often suffer from illness and trauma/injury in the presence of
several other comorbidities. This could, therefore, render many older hospital patients in a state
of hyper-metabolism or auto-cannibalism, resulting in excessive loss of muscle mass that may not
be apparent in pre-clinical studies in healthy volunteers [43–45]. RET and protein nutrition are
undoubtedly the most potent non-pharmacological interventions to maintain, or even increase, muscle
mass and function with advancing age [46]. Nevertheless, as performing RET may not be viable during
acute episodes of disuse, such as SR, ULI and BR, the purpose of this review is to summarise the
literature on nutritional strategies to minimise the loss of skeletal muscle mass and function in humans
during different experimental models of disuse. As such, nutritional interventions with the potential
to offset disuse atrophy may be a preferred approach in some clinical settings. Given the knowledge
that alterations in MPS appear to be a primary driver of disuse atrophy in young and old (at least
in healthy individuals), nutritional stimulation of MPS may be an effective way to arrest the decline
in muscle mass. Due to difficulties in the direct measurement of in vivo MPB rates, little is known
about the temporal time-course of MPB during different models of disuse and the overall contributing
role of MPB in disuse atrophy. As such, the effect of nutritional interventions on disuse-induced MPB
are relatively unknown. Hence, the primary focus of nutritional interventions to attenuate disuse
atrophy in older adults is on stimulation of MPS (i.e., overcoming anabolic resistance), the success of
which would likely differ between healthy older adults and those with a compromised health status
(Figure 2).
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Figure 2. Illustration of the effects of disuse events on mechanisms of disuse atrophy in older healthy and
diseased phenotypes and theoretical potential for nutritional interventions to mitigate these detrimental
effects. (A–C) The effects of disuse (bed-rest and unilateral limb immobilisation) and inactivity
(step reduction) on muscle protein synthesis (MPS), breakdown (MPB), net protein balance (NPB)
and muscle mass in healthy older adults, with the worst-case scenario (i.e., disuse with no nutritional
strategy) and best-case scenario (i.e., with potentially effective nutritional strategy). (D–F) The effects
of disuse and inactivity on MPS, MPB, NPB and muscle mass in older adults with compromised health
status (frailty, malnutrition syndrome, cachexia and chronic inflammatory disease) and the orst-
and best-case scenario. With nutritional intervention-only, the best-case scenario may result in more
positive NPB (alb it still negativ ) and an attenuated rate of muscle atrophy. NB: The improvem nt
in NPB outlined in the best-case scenario panels is driven primarily through nu ritional sti lation
of MPS, whereas nutrient-induced M s ppression plays a les er role (due to the absence of clear
evidence demonstrating MPB suppression with nutri ional terventions during disuse).
3. Nutritional Strategies during Disuse
3.1. Whole Food and Mixed-Meal Approaches
The “food-first” (or “whole-food”) approach, unlike isolated protein components (e.g., whey
protein and casein protein, discussed below), contain a variety of other non-protein derived nutrients
that may facilitate ntramuscular anabolic signalling, MPS and tissue emodelling [47]. This approach
has gained interest in human metabolic research where, compared with studies using isolated proteins,
several recent nvest gations have focused on the muscle anabolic r sponse following consumption of
protein-rich whole-foods, such as beef [48–50], eggs [51,52], skimm milk [50], po ltry [53,54] and
other mixed macronutrient meals [55–58]. However, an in-depth discussion of the food-first approach
vs. isolated proteins is beyond the scope of this review and has been discussed elsewhere [47,59].
It has recently been suggested that a high-quality protein whole-food approach can support muscle
mass throughout the lifespan [59], likely due to nutrient density, and non-nutritive components that
may facilitate muscle remodelling compared to pure, isolated protein sources [51]. High protein quality,
as measured by the protein digestibility-corrected amino acid score (PDCAAS) [60], the digestible
indispensable amino acid score (DIAAS) [61] or the leucine amino acid reference ratio (Leu-AARR) [62],
are critical in the promotion of MPS and long-term accrual of muscle mass [59]. However, as a blunting
of the MPS response to protein provision is observed with advancing age [56,63–65], one might
question whether providing protein-dense whole-foods is desirable in older or clinical populations
considering their prolonged satiating effect and relatively slow rate of gastric emptying [66,67],
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which may negatively affect overall daily dietary protein intake in a population already prone to
protein malnourishment. Indeed, it has previously been shown that older adults in an acute care
facility only consumed ~10 g of a commendably large ~40 g serving of protein at each meal [68].
The authors postulated that food taste, temperature, texture and preferences all play a role in protein
consumption within acute medical inpatient facilities. Furthermore, similar issues with sub-optimal
dietary protein consumption have also been observed in older adults undergoing elective hip/knee
surgery [69], whereby only ~30% of meal-time protein was consumed [9], clearly identifying the need
to consider other strategies to ensure sufficient protein to attenuate muscle loss is consumed by older
adults undergoing protracted disuse events. More specifically, following short-term hospitalisation
in patients with elective hip/knee surgery, it was shown that, despite patients being provided with
~0.8 g·kg−1·BW·day−1 of protein in self-selected hospital meals, actual protein consumption fell below
0.6 g·kg−1·BW·day−1. This was accompanied by a ~4% reduction in thigh cross-sectional area [69,70].
Furthermore, a recent seven-day BR protocol, with a diet composed of traditional inpatient mixed
macronutrient meals (~1.0 g·kg−1·BW·day−1 [~70% animal, ~30% plant proteins]) failed to attenuate the
decline in leg lean mass and strength in healthy older adults [71]. Although total provided protein intake
in both investigations provided the current RDA (0.8 g·kg−1·BW·day−1), they fell short of the current
clinical recommendations for older individuals during hospitalisation (~1.6 g·kg−1·BW·day−1) [72].
Therefore, the ingestion of additional volume of mixed meal proteins potentially may have offset
muscle loss but may also come at the expense of increased and prolonged satiety. Furthermore, it is
also pertinent to note that the amount of protein per kcal of food is less. Therefore, besides satiety, the
subdivision of macronutrients from the total daily caloric intake is likely sub-optimal.
An often-overlooked aspect of protein-rich whole-food approaches, when compared with isolated
sources, is the texture of the foods. This is particularly important for older adults who may have
impaired food chewing capabilities [73]. Evidence suggests that the partial processing via mincing of
protein-rich lean meats, such as beef, has been shown to increase protein digestion and absorption in
older adults, resulting in greater postprandial protein incorporation when compared with ingestion
of whole beefsteak [49]. However, it is important to note that, in this study, MPS rates did not
differ between these conditions when assessed over a 6-h postprandial period [49]. Nevertheless,
this method of protein processing and/or enhanced mastication of ingested foods may be a novel
method of increasing the amount, digestibility, and absorption of amino acids (AA) from protein-rich
whole foods, which may be especially important for older adults, particularly those undergoing disuse
or inactivity. Indeed, novel data in elderly volunteers who were edentulous, found a significantly
reduced postprandial rise in circulating plasma EAAs following a serving of lean beef meat, which
subsequently resulted in an ~18% reduction in whole-body protein synthesis compared with older
adults who had healthy natural dentition [74]. This poses the question as to whether older adults
may need softer textured or partially processed foods to increase protein consumption and, therefore,
postprandial AA availability and muscle anabolism. A comparison of distinct protein whole-foods
with divergent AA delivery profiles in healthy younger adults was conducted by Burd et al. in response
to protein dose-matched, skimmed milk or lean beef [50]. Although beef consumption resulted in
a ~7% greater AA availability over the initial 2 h postprandial period, skimmed milk consumption
stimulated a greater MPS response during this time frame. However, there were no differences in
MPS stimulation between beef and milk ingestion when assessed over a 5 h postprandial period [50].
Nevertheless, the trade-off between ease of ingestion and postprandial AA availability between these
common protein-rich food sources could present different muscle anabolic responses in older adults
during periods of disuse.
Protein-rich whole-foods undoubtedly promote muscle anabolism in the acute postprandial period
(~2–6 h) in healthy younger [51,52], older [49,50,75] and inflammatory disease patients [56]. Therefore,
the role of high-quality whole-food protein mixed meals in maintaining muscle mass should provide a
solid nutritional foundation in which supplementation can support (Figure 2). The anabolic concept of
the food matrix is principally demonstrated in the form of whole-egg and isonitrogenous amounts of
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egg-whites consumed post-RET [51]. Van Vliet and colleagues observed a greater post-RET stimulation
of MPS following whole-egg consumption, than that of egg whites [51]. Interestingly, the authors
detected no differences in postprandial leucine availability or intracellular anabolic signalling [51].
The authors therefore speculated that whole eggs are more than the sum of their parts. In particular,
non-nutritive components [i.e., bioactive peptides, microRNAs, lipids (phosphatidic acid, palmitic
and DHA) and minerals] may orchestrate the greater MPS response observed with whole-eggs and
not egg white consumption [51]. Follow-up investigations from the same group have established
whole-egg consumption results in greater co-localisation of mTOR-Rheb complexes to the lysosome
following RET than that of egg whites [52]. Nevertheless, the anabolic role of the food matrix is yet to
be established in older adults. Accordingly, older adults should seek to consume the recommended
dietary protein intake (~1.6 g·kg−1·BW·day−1), rich in nutrient-dense foods to attenuate loss of muscle
mass during disuse events. Unfortunately, in many disuse scenarios, the practicality of large daily
whole-food consumption in older adults is low. Therefore, the addition of rapidly digested isolated
proteins may be necessary to enhance protein quality, quantity and the net muscle anabolic effect of
typical sub-optimal protein-containing meals in older and clinical populations.
3.2. Supplemental Protein Sources
Whey protein (WP) and casein protein (CP) nutritional supplements are produced by separating
proteins from their naturally occurring whole-food derivative (i.e., milk). Studies investigating the
metabolic profiles of dairy-derived proteins demonstrate the rapid digestion and absorption kinetics
of isolated WP compared with the more slowly digested casein [76–78] and complete whole-milk
proteins [79,80]. Indeed, evidence exists to suggest WP possesses superior muscle anabolic properties
compared with casein. Specifically, following consumption of WP, the increase in MPS is greater than
casein, potentially due to the superior AA profile and postprandial leucinemia of WP [77]. However,
not all authors have observed a benefit of WP over its whole-milk component for muscle anabolism,
despite temporal differences in aminoacidemia [81,82]. This may be partly due to the whole-food
matrix and added macro-micronutrient value of whole milk, which may facilitate the potent and rapid
increase in MPS. Moreover, the measurement duration, protein dosage and synergistic effect of RET
likely influences the subtle differences or similarities observed between whole milk protein, isolated
WP, and CP derivatives on acute measures of postprandial MPS. Nevertheless, high-quality leucine-rich
WP supplementation has been shown to induce a greater postprandial MPS response in both younger
and older adults compared with other dose-matched isolated protein sources (e.g., soy, casein and
wheat) [78,83] under conditions of rest and exercise [78]. Evidence also exists to support the use of WP
during inactivity and disuse. Indeed, recent investigations have found WP to be effective in offsetting
BR-induced muscle deterioration in older adults [71]. Furthermore, Arentson-Lantz et al. (2019)
demonstrated that replacing whole-food mixed meal proteins with WP (i.e., improving protein quality),
attenuated the decline in whole-body lean tissue during seven days of BR. Importantly, dietary protein
intake was relatively low in this study (~0.9 g·kg−1·BW·day−1) and, therefore, more representative of
the eating habits of older adults within inpatient facilities [69].
Others have attempted to navigate the issue of dietary protein malnutrition during BR with the
implementation of blended mixed protein complete meal replacements [WP, CP, pea protein and
soy protein] [41]. Specifically, Dirks et al. (2019) provided volunteers with a standardised diet of
~1.2 g·kg−1·BW·day−1 of dietary protein, introduced via nasogastric tube by four intermittent protein
boluses or via a 24-h continuous feeding approach [41]. Interestingly, the findings suggested that the
delivery method of dietary protein did not influence the negative consequences of BR on skeletal
muscle mass, strength and metabolic function. In addition, it is of interest to note that the total amount
of dietary protein (~1.2 g·kg−1·BW·day−1) was insufficient at protecting losses in muscle mass [41].
During ULI, the use of isolated dietary proteins have been reported to have no effect on skeletal
muscle mass and strength loss in healthy older males when compared with a placebo [84]. Specifically,
Dirks et al. (2014) used a five-day whole-leg cast immobilisation approach with and without WP
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supplementation (2 × ~21 g daily [10.6 g EAAs, 2.8 g leucine per drink]), which increased daily
protein intake from ~1.1 to ~1.6 g·kg−1·BW·day−1. Others have also shown no beneficial effect of
protein supplementation during more extended periods of ULI (~14 days), in healthy middle-aged
males [85], albeit with lower daily supplemental strategies (1 × 20 g). Mitchell et al. (2018) observed
no benefit of a single daily bolus of ~20 g milk protein with breakfast on preventing loss of muscle
mass and strength during a habitually skewed dietary protein intake of 1.0 g·kg−1·BW·day−1 (breakfast
25%, lunch, 25% and dinner 50% of energy and protein requirements) to represent typical eating
habits of older individuals [85]. Although current data are inconclusive on the effects of WP during
ULI, further investigation into other WP strategies (e.g., dosage (~40 g) [86], timing [87], pre-sleep
consumption [88], pattern distribution [89] and additional free-form leucine [90]) could offer protection
against disuse atrophy.
To date, there has only currently been one randomised controlled trial (RCT) of the influence of
dietary protein during an SR model [24]. Oikawa et al. (2018) found that a high quality, high-protein
diet (~1.6 g·kg−1·BW·day−1) during SR (~750 steps day−1) and a ~500 Kcal energy deficit for two weeks,
failed to attenuate muscle atrophy in older adults. Specifically, the provision of two daily WP drinks
(providing ~30 g protein each (15.4 g EAA, 4.3 g leucine) or a protein-matched hydrolysed collagen
peptide drink (4.5 g EAA, 0.8 g leucine) during SR failed to attenuate the reduction (~14%) in free-living
MPS [24]. An important observation from this study is that a seven-day transition from energy balance
to energy restriction evoked a decline in MPS (~12%), even in the presence of double the current protein
RDA (~1.6 g·kg−1·BW·day−1). Alarmingly, Oikawa et al. (2018) also found that, following a seven-day
period of re-ambulation, MPS was not fully restored to levels pre-intervention levels, highlighting the
importance for an appropriately prescribed rehabilitation and nutrition program following a period of
disuse in older adults [24]. Nonetheless, whilst WP supplementation failed to prevent the loss of lean
tissue during SR, WP did promote a greater recovery of lean tissue upon reambulation [24].
Although isolated proteins have been shown acutely to stimulate postprandial MPS and augment
the muscle anabolic response to RET, these isolated ingredients, in particular high-quality WP, may
be relatively ineffective at attenuating muscle atrophy during disuse in older adults. This may be
due to the relatively good health of older volunteers in these studies, or possibly the relatively high
level of total combined daily dietary protein intake (meals, plus supplementation) provided in these
studies (~1.6 g·kg−1·BW·day−1 [24,84]). Therefore, greater relative daily amounts (>2 g·kg−1·BW·day−1),
combined with novel isolated intact protein blends as well as protein sources containing high relative
proportions of di- and tripeptides (i.e., protein hydrolysates), may be needed to facilitate greater
protective effects on muscle during disuse. Indeed, whilst evidence is limited, protein hydrolysates
have been observed to be superior to intact proteins, largely due to decreased splanchnic extraction,
increased postprandial AA bioavailability and rapid appearance of EAAs, in particular leucine, into
circulation [78,91–93]. Moreover, WP hydrolysates have also been observed to augment a greater acute
postprandial MPS response compared to intact protein sources in younger and older adults [78,91,93].
However, ultimately, more chronic investigations are required to assess the longer-term anabolic
potential of protein hydrolysates compared with intact (whole) proteins, particularly during periods
of disuse and inactivity. Nevertheless, protein supplementation may, however, be of use to older
adults with compromised health status (i.e., pre-existing anabolic resistance) or those who consume
low levels of dietary protein (i.e., <0.8 g·kg−1·BW·day−1) [94], which is particularly prevalent during
illness/hospitalisation.
3.3. Crystalline Amino Acids
During periods of inactivity and disuse, the consumption of whole-food mixed meals or even
isolated protein sources may not be feasible, primarily due to the aforementioned issues of appetite
and satiety regulation that are common in older adults. Therefore, constituent free-form AAs as either
a complete EAA profile (i.e., all nine EAAs) or individual AAs (i.e., leucine) that possess anabolic and
anti-catabolic properties may be an effective and energetically efficient in offsetting muscle atrophy.
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The following section discusses the efficacy of AA supplementation in a range of modes of disuse
and inactivity.
3.3.1. Essential Amino Acids
Isocaloric consumption (15 g) of EAAs (2.79 g leucine) in older individuals has been shown
to result in a >30% increase in MPS compared to a protein-matched ~15 g WP (1.75 g leucine) [95],
likely due to the higher proportion of EAAs and more rapid digestion and absorption of crystalline
EAAs. A follow-up investigation found that, when matched for EAA content, ~15 g of WP resulted
in a greater accrual of muscle proteins compared to 6.7 g of EAA, overall indicating that the content
of EAA within WP is likely not the sole explanation for its anabolic superiority to pure EAAs [96].
As discussed above, an important consideration regarding protein nutritional strategies in older adults
is the dosage required for maximal MPS stimulation (EAA, ~15 g, WP, >30 g), and their respective
effects on appetite and satiety [97]. Recent evidence comparing an EAA-matched dose of WP ~15 g
(7.5 g EAA, 1.9 g leucine) to crystalline EAA (7.5 g, 3.0 g leucine) prior to breakfast in older adults,
found that EAA supplementation resulted in greater protein and energy intake compared to WP.
In addition, consumption of EAAs did not affect appetite ratings or satiety hormones (i.e., PYY),
compared with WP [98]. Furthermore, it is pertinent to note that EAA, when ingested with meals,
is known to significantly increase the postprandial MPS response by ~30%, but without affecting
circulating glucose or insulinemia [99].
In human metabolic research, much like isolated proteins, dosing strategies for EAAs range
considerably: from ~1.5 g [100], ~3 g [101,102], ~10 g [103], ~15 g [104] and ~18 g [105] to >20 g [106,107].
Early studies showed that consumption of ~15 g EAAs thrice daily for ~28 days of BR in young males
resulted in maintenance of whole-body and leg lean mass compared with the placebo control [36],
which was associated with a maintenance of MPS. Importantly, similar observations have also been
found following ~10 days of BR in older adults [108]. Thus, supplementing with EAAs in-between
meals during periods of BR, as previously established in both younger [36,109] and older adults [108],
may offer a viable option for repeated and frequent MPS stimulation, without impacting satiety
(Figure 2) [99].
In models of ULI, recent evidence regarding AAs, particularly a novel AA blend with additional
non-essential AAs (NEAA)—arginine, glutamine and n-acetylcysteine—has been shown to mitigate
muscle atrophy associated with seven days of ULI in healthy young men [110]. Indeed, as the authors
stated, it is possible that certain NEAAs may function by attenuating catabolism (i.e., glutamine),
maintaining capillary perfusion (i.e., arginine) and reducing oxidative stress (i.e., n-acetylcysteine),
which have all been implicated in disuse atrophy [111–115]. Specifically, the consumption of an
EAA:NEAA supplement in between meals (3 × 23.7 g = ~71.1 g EAA:NEAA, totalling ~12 g leucine
per day) attenuated muscle atrophy and increased intramuscular lipid accumulation compared with
a placebo [110]. It is, however, important to note that this study implemented a seven-day loading
period of the high-dose EAA:NEAA blend, prior to and during the seven-day period of ULI, which,
whilst possible for older adults prior to anticipated disuse events (i.e., elective surgery), would not be
possible in acutely hospitalised patients. Furthermore, participants were provided with >70 g AAs
on top of a standardised 1.0 g·kg−1·day−1 of dietary protein. The large amounts of AAs provided
by Holloway and colleagues, whilst providing proof of concept, lack real-world practicality [110].
Interestingly, however, leucine-enriched (40%) low EAA dosages of ~3 g (1.2 g leucine, 1.8 g EAA) have
been shown to augment similar increases in MPS to that of ~20 g WP (2 g leucine, 7.6 g EAA) in older
women [101]. Further, dosages as low as ~1.5 g EAA (0.6 g leucine, 0.9 g EAA) have been reported
to stimulate an equivalent MPS stimulation to a large (~40 g) bolus of WP (4 g leucine, 15.2 g EAA)
in healthy older women [100]. The addition of ~15 g of EAAs in between, and more importantly, to
sub-optimal protein containing meals may therefore be a strategy to mitigate negative effects of disuse
and inactivity (Figure 2). This is particularly applicable within in-patient facilities where low-protein
consumption and satiety may be of particular concern for older adults.
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3.3.2. Leucine
Of the EAAs, the branched-chain AA leucine, has been shown in multiple human models to be a
key mediator of postprandial MPS in healthy younger and older adults [90,100,116–118], and also in
response to acute bouts of RET in the presence of a complete protein source [100,101,119,120]. Leucine
has previously been found to have a protective effect on skeletal muscle mass and function during
14 and 7 days of BR in healthy middle-aged [37] and older adults [121], respectively, in the presence of
a complete protein source. English et al. (2016) reported that supplementation of a high dose of leucine
(0.06 g·kg−1·BW·meal−1 or ~5 g) per meal, attenuated the decline in postabsorptive MPS, muscle mass
and muscle strength following 14 days of BR compared with a placebo [37]. Similarly, following seven
days of BR in older adults, the same previously mentioned leucine strategy attenuated the loss of leg
lean mass; however, no effect was observed for muscle strength or function. Moreover, leucine did
not mitigate the effects of BR on muscle fibre CSA or intracellular catabolic protein expression [121].
However, these findings are in agreement with other seven-day ULI protocols which also found no
protective effect of leucine supplementation on quadriceps CSA or leg strength [122]. It remains
unclear whether the disuse model (BR, ULI or SR), dosage (13.2 g vs. 7.5 g per day) and/or timing of
leucine intake (i.e., with or without meals) is attributable to these observed differences and warrants
further research.
The role of leucine as a stand-alone nutritional strategy therefore displays equivocal effects at
maintaining muscle mass and anabolism. This is particularly important as it is impossible for MPS
to exceed MPB when the AA substrates are derived entirely from MPB, and therefore a net positive
protein balance cannot occur in the absence of an exogenous supply of a complete EAA profile [123,124].
Nevertheless, ~6 g of leucine containing BCAAs have been previously shown to trigger intracellular
anabolic signalling, and augment a small, but significant increase in short-term MPS in younger [125]
and older adults [126]. However, in the absence of a full EAA profile, leucine fails to provoke a
robust and prolonged state of postprandial MPS as displayed by a traditional ~20 g dose of WP [124].
Therefore, the role of leucine may not be as a stand-alone supplement, but in fortifying complete
proteins with additional free-form leucine to augment a greater anabolic effect. Indeed, this has been
observed in fortifying low, suboptimal dosages of protein that have been observed to elicit similar
acute increases in MPS to that of >25 g of protein [100]. Therefore, it is plausible to suggest that a lower
quantity, leucine-enriched protein dose may alleviate some of the satiating effects of a larger protein
bolus, as discussed above, whilst still facilitating a net positive protein balance [127], thus supporting
the maintenance and/or development of muscle mass in older adults [117,118].
3.3.3. Citrulline
With a lack of evidence to support the use of non-essential AAs (NEAA) in supporting protein
accretion, particularly models of disuse [12,13,15,24,128–131], there is currently only one study to
have utilised NEAA, albeit in the form of the single non-essential AA, citrulline [128]. Devries and
colleagues postulated that, as a precursor of nitric-oxide, the consumption of citrulline would enhance
vasodilatory nutrient delivery to skeletal muscle and attenuate inactivity-induced impairments in
MPS in older men [128]. However, purported vasodilatory nutrients have shown little success in
augmenting vasodilation, and evidence suggests that even potent pharmacological manipulations of
blood flow and tissue-specific microvascular circulation do not enhance postprandial MPS [132–134].
Therefore, it is unsurprising that nutrient derived vasodilatory compounds; AAs (i.e., citrulline and
arginine) [112,128,135–137] and other nutraceuticals with purported vasodilatory properties (i.e., cacao
flavanols and Montmorency tart cherry) [138,139] have failed to elicit any notable muscle anabolic
effects. Indeed, Devries et al. were unable to demonstrate any effect of daily supplementation of
citrulline on femoral blood flow or MPS [128]. Nevertheless, one study has found a beneficial effect
of pharmacologically manipulating vasodilation on MPS under conditions of a hyperinsulinemic
clamp in older adults [140]. Notably, under normo-insulinemic conditions, such beneficial effects
on MPS have not been replicated [141]. The implementation of purported vasodilatory nutrient
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compounds, therefore, may not be beneficial for enhancement or maintenance of MPS and muscle
mass during inactivity and/or disuse in older adults. By direct contrast, vasoconstriction (induced via
cold water immersion) has been shown to attenuate the post-exercise increase in MPS by ~20% [142],
which may have important implications during disuse and/or periods of hospital stay but warrants
further investigation.
3.4. Beta-Hydroxy-Beta-Methyl Butyrate (HMB)
Beta-Hydroxy-Beta-Methyl Butyrate (or HMB) is a downstream metabolite of leucine metabolism
in skeletal muscle, with a physiological turnover rate of ~0.2–0.4 mg per day or 0.66% of total leucine
turnover [143]. HMB, as an oral nutritional supplement, is commercially available in both calcium-salt
(Ca-HMB) and free-acid forms [144], both of which have been shown in acute in vitro [145–147] and
in vivo human models to stimulate MPS and dampen MPB [144,148]. Furthermore, it is also pertinent
to note that use of HMB may also be associated with anti-inflammatory effects, although such findings
are equivocal [149,150].
Early studies investigating the use of HMB in healthy individuals undertaking RET, demonstrated
a highly potent anabolic effect [151–154]. Specifically, one study observed significant improvements
in body composition and muscle strength, which were associated with a ~20% reduction in MPB
(assessed via urinary 3-Methylhistidine excretion) and reductions of indirect markers of muscle damage
(i.e., creatine kinase and lactate dehydrogenase) [155]. However, more recent RCTs [156–159] and
meta-analyses [160,161] have failed to detect any benefit (i.e., increases in muscle mass, strength or
function) of HMB in trained [162] or clinical populations [161]. Nevertheless, HMB is still considered a
nutritional compound that may possess the potential to attenuate the rate muscle loss during ageing
and disuse [160,163–166].
The use of HMB supplementation during 10-days BR (1.5 g Ca-HMB, twice daily) has been
shown to attenuate muscle anabolic resistance and atrophy compared with a placebo in healthy
older adults [165]. Importantly, Ca-HMB in this study, attenuated BR-induced muscle atrophy under
conditions of a sub-optimal dietary protein intake [165]. Further, following 10-day BR, the placebo
group reported a significant loss of whole-body (~5% vs. 1%), and lower limb (~7% vs. <1%) skeletal
muscle mass compared with Ca-HMB, respectively. Similarly, following a standardised liquid meal,
whilst postprandial MPS remained unchanged in the Ca-HMB group following 10-day BR, a ~23%
reduction in postprandial mixed-MPS was observed in the placebo group [165]. Subsequent follow-up
investigations by Standley et al. sought to determine the effects of Ca-HMB on skeletal muscle oxidative
function from a sub-sample of older participants, in which mediators of mitochondrial and lipid
metabolism were assessed [165,166]. In contrast to previous investigations, Ca-HMB displayed no
effect on mitochondrial oxidative phosphorylation, dynamics (fission and fusion) or autophagy between
Ca-HMB or placebo supplemented groups [166]. However, Ca-HMB supplementation did increase
the intramyocellular lipid pool, particularly triacylglycerol lipids, which the authors speculated may
have protected skeletal muscle from inflammatory and reactive oxygen species-stimulatory lipids.
In vitro data suggests HMB alters myotube lipid biosynthesis and upregulation of fatty acid synthase,
which may facilitate anabolic processes and offer protection of muscle cells from other bioactive lipid
species [167]. To date, however, the exact mechanisms through which supplemental HMB may act to
protect muscle mass during disuse events in older adults remain unclear.
Studies investigating the effect HMB on disuse atrophy, unlike many nutritional strategies, have
transitioned into clinically relevant models of critically ill older adults, across a range of patient
populations, including patients suffering with malnutrition [168], within intensive care units [169],
cachexia patients [170] and patients with HIV [171]. A recent systematic review and meta-analysis
conducted by Bear et al. (2019) showed that the data surrounding HMB supplementation are relatively
limited (n = 13 studies), particularly when provided in isolation and not as part of a mixed nutrient
“cocktail” (n = 3). For example, HMB is often consumed with other AAs (i.e., arginine and glutamine)
or as part of a multi-ingredient oral nutritional supplement (e.g., with additional protein and vitamin
Nutrients 2020, 12, 1533 11 of 26
D) [161,172,173]. Therefore, as a stand-alone nutritional supplement, more high-quality RCTs are
needed to establish HMB’s role in mitigating the loss of muscle mass and strength during disuse events,
particularly in older clinical populations.
3.5. Creatine Monohydrate
Creatine monohydrate (CM) has been a popular sports supplement with athletic populations
for over three decades, with purported significant improvements in muscle mass and strength when
combined with RET in young and older adults [174–176]. The potential mechanisms through which
creatine exerts its beneficial effects are founded on three underlying anabolic constituents. Firstly,
CM has been reported to increase osmo-sensing proteins related to signal transduction [177] and
targeted mRNA gene expression [178]. Secondly, CM is purported to have an indirect role in muscle
anabolism through the phosphorylation of primary downstream anabolic signalling proteins and
inhibition of the myokine, myostatin [179]. However, isotopically labelled tracer studies have failed
to detect any increases in mixed-muscle, myofibrillar and/or sarcoplasmic MPS following RET and
CM supplementation [180–182]. However, CM has been reported to have anti-catabolic properties
via a reduction in leucine oxidation [181] and urinary 3-methylhistidine excretion [183]. Finally, CM
has been suggested to augment muscle satellite cell activation [184,185]. Therefore, with a growing
body of literature suggesting that CM can increase muscle mass and strength in older adults [175,176],
it has been postulated that CM may also provide some muscle anabolic benefit during periods of
musculoskeletal disuse [186,187].
During periods of disuse, Johnston et al. showed that oral CM supplementation (~20 g per day)
provided up to three weeks of beneficial effects during a period of upper-arm ULI in healthy younger
adults by supporting the maintenance of lean muscle mass, strength, and endurance to a greater
extent than a placebo [186]. The potential for CM to attenuate muscle deterioration has also been
studied in the context of lower-limb ULI in younger adults [187]. Specifically, following a seven-day
loading phase and seven-day maintenance dose pattern of oral CM supplementation (loading Phase:
4 × 5 g day, maintenance: 1 × 5 g day), CM did not attenuate the loss of muscle mass or strength
following ~7 days of ULI compared to a placebo control [187]. Whilst, the mechanisms of CM in
models of disuse remain unclear, an exploration into the effects of in vivo skeletal muscle creatine
sensitivity and transportation may offer insight into the uptake of creatine into muscle cells [188,189].
Nevertheless, the current available evidence regarding its lack of stimulatory effect on MPS, combined
with the requirement of a loading phase, suggests that CM supplementation is likely an inadequate
and impractical nutritional intervention, at least in isolation, during models of disuse. However, MPS
methodologies and disuse interventions have yet to be established in older adults, therefore, we cannot
rule out a potential therapeutic benefit of CM in such populations.
3.6. Omega 3 (n-3) Fatty Acids
Marine fish oils, particularly n-3 FAs rich in Eicosatetraenoic (EPA) and Docosahexaenoic (DHA),
have been shown in both young and older adults to be key signalling mediators of skeletal muscle
anabolism [190–192], insulin sensitivity [193,194] and inflammation [195]. Human studies utilising
intravenous hyperinsulinemic and hyperaminoacidemic clamps have shown a moderate dose (~4 g) of
n-3 FA supplementation, augments MPS rates in healthy young [190], middle-aged [190] and older
adults [192]. Further, McGlory et al. demonstrated that eight weeks of daily n-3 FA supplementation
resulted in a ~23% increase in myofibrillar MPS, compared with a placebo, following a bolus feeding of
WP in young men, although this was not statistically significant [196]. However, n-3 FA supplementation
was associated with a suppression of resistance exercise and feeding-induced increases in anabolic
signalling phosphorylation [196]. In older adults, data suggest ~16 weeks of moderate-to-high dosage
of n-3 FA (~4 g·day−1) increase the postabsorptive and post-RET (~15–18 h) rates of mitochondrial and
myofibrillar protein fractions in healthy older adults [191]. Moreover, long-term supplementation of
n-3 FA (~6 months) resulted in significant increase in thigh muscle volume and strength in the absence
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of RET [197]. Collectively, evidence from these studies forms the basis of n-3 FA supplementation as a
potential strategy to counteract disuse atrophy in older adults.
During a 14-day period of ULI, n-3 FA have been shown to attenuate declines in muscle mass in
healthy young women compared with an isoenergetic placebo (i.e., sunflower oil) [198]. In addition,
daily supplementation of dosages of ~5 g·day−1 of n-3 FA resulted enhanced myofibrillar MPS and
restored muscle mass over 14 days of reambulation following disuse [198]. The mechanism through
which n-3 FA may protect against disuse atrophy might be, in part, explained by an increase in the
total phospholipid content of the muscle cell [199]. It is, however, pertinent to note the methodological
considerations in the implementation of n-3 FA, in particular, the fundamental loading phase prior
to a period disuse. Whilst McGlory and colleagues observed temporal changes in skeletal muscle
phospholipid content, a minimum of two weeks (and up to four weeks) of supplementation was
required to sufficiently elevate and saturate muscle cell membranes with EPA:DHA [200]. Importantly,
it would seem that higher doses of EPA+DHA are required to achieve a more rapid saturation
(~2-fold increase in four weeks) [200,201] of muscle cell phospholipids than previous used lower doses
(~2-fold increase in eight weeks) [190,192]. However, the temporal changes in skeletal muscle EPA:DHA
content have yet to be established in older adults [202]. Moreover, n-3 FA have currently yet to begin
translation into older adults and across other experimental models of disuse and inactivity [202].
Interestingly, when considering a food-first approach to nutrient delivery in older adults
undergoing disuse events, recent evidence suggests that consuming n-3 FA rich foods offer similar
benefits to EPA:DHA status as dietary n-3 FA supplementation [203]. Carboni et al. recently reported
thrice-weekly feeding of cooked mussels consumed for lunch over four weeks, resulted in an ~18%
increase in n-3 index, as well as a ~40% increase in whole-blood levels of EPA:DHA [203]. Importantly,
the EPA:DHA content of cooked mussels in this study was considerably lower (~300 mg) compared
with previous investigations (>3000 mg) [190,191,199,200], suggesting that a substantially longer
period of time and/or larger doses of n-3 FA rich meals would be required to achieve an optimal
n-3 status. Taken together, whilst there is a lack of research across different models of disuse/inactivity,
particularly in older patient populations [202,204], the available data suggest a potential benefit of
daily n-3 FA supplementation for maintenance of muscle mass in older adults during periods of
disuse and/or inactivity, with the caveat that any protective effect may depend on whether a loading
phase is possible prior to disuse (i.e., elective surgery patients). However, it is pertinent to note that
n-3 FA are also anti-inflammatory and thus, may provide additional benefit to inflammatory disease
patients [205,206]. Indeed, lowering inflammation would have a plethora of potential beneficial effects
besides maintaining muscle mass [205,206]. However, more studies are required to investigate this
further, particularly in models of disuse.
3.7. Multi-Ingredient Supplements
In isolation, the use of single-ingredient nutritional compounds, previously mentioned, may not
be sufficient to fully attenuate disuse atrophy in both younger and older adults. Nevertheless, a more
comprehensive multi-ingredient supplement (MIS) with several purportedly beneficial compounds
(i.e., WP, EAAs, creatine, vitamin D, leucine, glutamine, HMB and n-3 FA’s) [207], may be a superior
alternative to help support the maintenance of muscle mass and strength during ageing. However,
whilst a recent systematic review and meta-analysis encompassing ~35 RCTs utilising MIS as part of a
~6-week training intervention observed MIS as not superior to WP alone in healthy trained populations;
MIS was shown to be beneficial in older and untrained adults undertaking a period of multi-modal
concurrent exercise [208–210]. Furthermore, the majority of studies investigating the use of MIS also
implement RET as part of the intervention, and therefore, this may mask any beneficial effects that
might been seen with the supplement alone.
Nevertheless, evidence has emerged to demonstrate that a MIS compromising of WP (30 g),
creatine (2.5 g), vitamin D (500 IU), calcium (400 mg) and n-3 FAs (1500 mg) may have a beneficial effect
on skeletal muscle mass and strength [208,211], inflammation [212] and cognition [213] in older adults,
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although no effect on exercise-induced myogenesis was observed [214]. MIS, however, did not benefit
the adaptive remodelling response to a 12-week multi-modal, concurrent RET and high-intensity
interval training intervention in older men [215]. Specifically, Bell and colleagues observed no benefit
of twice-daily consumption of a WP-based MIS (WP 30 g, creatine 2.5 g, vitamin D 500 IU, calcium
1500 mg, n-3 polyunsaturated fatty acid 1500 mg) on integrated measures of myofibrillar MPS compared
with a carbohydrate-based placebo. This is intriguing as the treatment group consumed ~30–40 g
(0.4–0.5 g·kg−1·BW·day−1) more protein over the experimental period than the carbohydrate control
group [208,215]. Although there is currently no evidence supporting the MIS approach both acutely
and in older adults during disuse, it is plausible that a blend of multiple beneficial compounds
(i.e., EAA, creatine, leucine, HMB, vitamin D and n-3 FAs) may be advantageous in targeting multiple
dysfunctional signalling mechanisms associated with disuse and/or inactivity, when combined.
4. Conclusions
BR, ULI and SR models can result in dramatic losses of muscle mass, strength and ultimately,
functional capacity in a relatively short period of time (2–14 days), with important implications for the
functional and metabolic health of older individuals. Although RET interventions are undoubtedly the
most potent regulator of muscle protein turnover and promising means of maintaining muscle mass
during inactivity, this approach may not always be feasible. Therefore, optimising nutritional intake
via high-quality proteins, food-fortification and/or oral nutritional supplements could potentially
attenuate disuse-induced impairments in muscle protein turnover that drive the atrophy process.
An underlying theme throughout the present review is the lack of translational research from healthy
younger and older adults, to frail and hospitalised older patient populations. Current clinical research
often includes older adults with high functional capacity and physical activity status, who consume a
nutritionally complete diet. Targeting musculoskeletal disuse in older adults with a compromised
health status is a stern test of whether or not a nutritional food/ingredient is efficacious, due to
the multifaceted nature of mechanical unloading and the progression of sarcopenia. We suggest
that a nutrient-rich whole-food dietary approach, providing adequate levels of high-quality protein,
is the foremost strategy to protect muscle mass and function in older adults undergoing disuse events.
Additional targeted single and/or multi-ingredient supplements may facilitate accrual and retention
of muscle tissue during disuse events, and may be a preferable strategy in older adults who are
unable to consume adequate high-quality dietary protein from whole-foods alone. Further research
should, therefore, seek to determine the temporal change in muscle protein turnover during disuse
events and translate promising evidence of potentially beneficial nutritional supplements/ingredients
into a clinically relevant setting. This approach will allow researchers to identify optimal times at
which to intervene with pragmatic nutritional strategies that can effectively attenuate/prevent muscle
metabolic dysfunction, atrophy and impairments in whole-body metabolism in older adults across
the health spectrum. Finally, it is worth noting that, in this review, our focus is predominantly on
positively influencing MPS and MPB and, thus, not explicitly on the potential beneficial effects that each
supplemental strategy might have on other metabolic functions. In this regard, whole-body protein
turnover studies need to be conducted to improve our understanding on the impacts to whole-body
(protein) metabolism during periods of disuse.
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